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The kinetics of complex formation between recombinant hirudin or recombinant hirudin mutants with thrombin were 
analyzed. In order to elucidate the inhibitor's reactive site peptide bond predetermined amino acid substitutions were 
introduced atpositions of basic amino acid residues by means of site-directed mutagenesis of a hirudin gene. In compari- 
son to recombinant hirudin (Ki = 19 pM) only those mutant inhibitors which were modified at amino acid position Lys 47 
showed ahigher K~ value for their complexes with thrombin. The observed effects are mainly due to increased kofr ate 
constants. 
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1. INTRODUCTION 
Hirudin is a polypeptide of 65 amino acid 
residues found in salivary gland secretions of the 
leech Hirudo medicinalis (review [1]). This protein 
forms stoichiometric omplexes with thrombin, 
the central serine proteinase of blood coagulation, 
in which the catalytic functions of the proteinase 
are blocked. 
The major common structural feature of pro- 
teinase inhibitor proteins is the primary contact 
region (= reactive site loop). The conformation of 
this loop is complementary to the surface of en- 
zymes and stands out from the inhibitor to become 
accessible to the active sites of proteolytic enzymes 
[2]. Thus the reactive site amino acid residue 
becomes bound to the specificity pocket of the pro- 
teinase. With respect to thrombin specificity one of 
the three lysine residues is thought o be the reac- 
tive site peptide bond. Especially the hirudin 
region around Lys 47 shows a sequence homology 
to a target sequence of a-thrombin in the pro-part 
(positions 148-157) of its precursor [3]. On the 
other hand, the kinetics of the hirudin-thrombin 
interaction indicate that a single hirudin molecule 
may occupy more than one site on a~-thrombin, 
one being the catalytic site and the other being 
distinct from the catalytic site and whose binding 
is dependent on ionic strength [4]. 
This paper deals with site-directed mutagenesis 
of  a hirudin gene and the kinetics of  mutant in- 
hibitor proteins with thrombin in comparison to 
natural and recombinant hirudin (r-hirudin). 
These studies were performed to determine 
whether there is a reactive site peptide bond in 
hirudin, which is directly involved in the thrombin- 
hirudin interaction, as has been shown for other 
proteinase inhibitor proteins and their corre- 
sponding proteinases. 
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2. MATERIALS AND METHODS 
Hirudin gene mutants were generated via the M13 gapped- 
duplex DNA approach [5] using ofigonucleofides of 17-25 bases 
carrying the synthetic marker. E. coli strains BMH 71-18: 
(A(iac, proAB),~hi, supE; F' iacI q, ZAMI5, proA+B+); BMH- 
71-18 routS: (BMH 71-18, mutS215::Tnl0); MK 30-3: 
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(A(lac,proAB), recA, galE, strA; F' lacI% 7_AMI 5, proA+B +) 
and phages M13mp9am and Ml3mp9rev were a gift from Dr 
H.-J. Fritz, Munich. Gene mutants were identified by dot-blot 
analysis of phages with 32p-labeled oligonucleotides [6] and 
dideoxy sequencing of recombinant ssMI3 DNA template [7]. 
Mutant hirudin gene fragments were isolated from ds M13 
DNA after gel electrophoresis on 5°10 polyacrylamide gels [8] 
and gel elution [9]. Expression and isolation of r-hirudin 
variants were performed from periplasmic fractions of E. coli 
[10] as described for r-hirudin [11]. The amino acid sequences 
of Ile 27-, Ile 36-, Ile 4L, Glu 36- and Glu47-hirudin were verified by 
amino acid sequence determinations [12]. Protein concentra- 
tions of r-hirudin variants were determined by RP-HPLC using 
standard solutions of recombinant hirudin. Bovine cr-thrombin 
was isolated as described [ 13,14] and the purity was ascertained 
by 10 steps of Edman degradation, c~-Thrombin concentrations 
were determined by active site titrations [15]. r-Hirudin isola- 
tion procedures were monitored by a thrombin inhibition assay 
with tos-G-P-R-p-nitroanilide (Boehringer) as substrate for 
thrombin. Assays were performed in polystyrene cuvettes at 
25°C in 0.1 M Tris-HCl, 0.2 M NaCl, 0.05010 Triton X-100, pH 
8.3. For the kinetics of hirudin and thrombin the same buffer 
conditions were applied. Tos-G-P-R-7-O-methyl)coumaryl- 
amide (Bachem) was used as a substrate for thrombin at con- 
centrations of 20-25/zM (= 4-5-fold Kin). Under the specified 
conditions the Km of the substrate was 5.2/~M. Concentrations 
of thrombin were 10 pM for experiments with natural hirudins 
and 20-25 pM for experiments with recombinant hirudins and 
mutants. Inhibitor concentrations were 10-80-fold over [E0] (= 
10-25 pM). Assays were performed with an Aminco SPF-500 
spectrofluorimeter operating in the ratio mode (Acx = 383 nm; 
,~cm = 455 nm) and fluorescence intensities were calibrated with 
7-amino-4-methylcoumarin solutions of known concentrations. 
3. RESULTS 
3.1. Construction and expression o f  hirudin 
variants 
As the reactive site peptide bond of a proteinase 
inhibitor protein determines its specificity the 
alteration of this amino acid residue should lead to 
a decreased affinity for its target proteinase. Con- 
cerning thrombin specificity we decided to 
generate hirudin mutants with single amino acid 
substitutions: in order to obtain definite results 
positions of basic amino acid residues hould be 
replaced by apolar, uncharged and polar, negative- 
ly charged amino acid residues, respectively. Ac- 
cording to the codons created by chemical gene 
synthesis [16] the AAA codons for Lys 27, Lys 36 
and Lys  47 were changed to ATA for Ile and AGA 
for Glu; the CAG codon for His 51 was altered to 
CTC for Leu and GAC for Asp by the method of 
oligonucleotide-directed site-specific ,mutagenesis 
via the gapped-duplex (gd) DNA approach. 
50-80°70 of examined clones showed the desired 
point mutation as could be verified by dot-blot 
hybridization of phages and dideoxy sequencing of 
positive clones. HindIII gene fragments of hirudin 
variants were obtained from ds Ml3mp9rev and 
inserted downstream of the alkaline phosphatase 
signal sequence as described for r-hirudin [11]. Ex- 
pression products were isolated in yields of 
2-6 mg/l bacterial culture. 
3.2. Pre-steady-state kinetics of  the interaction o f  
thrombin with hirudin, recombinant hirudin 
and recombinant variants 
Under assay conditions of 10-25 pM thrombin 
and 0.1 M Tris-HCl, 0.2 M NaC1, 0.05°70 Triton 
X-100, pH 8.3, all the inhibitors can be classified 
as fully competitive, slow binding inhibitors 
[ 17,18] of thrombin. Therefore, in slow binding in- 
hibition experiments with natural hirudin enzyme 
concentrations of 10 pM were used to obtain 
reliable data for the pre-steady state, whereas for 
r-hirudins 20-25 pM thrombin gave good results. 
In the presence of buffer, substrate and the ap- 
propriate slow binding inhibitor the reaction was 
started by the addition of enzyme. After a rapid in- 
itial phase the initial velocity decreased to a slower 
steady state (fig. 1). For each of the inhibitors a set 
of progress curves for several inhibitor concentra- 
tions was obtained and data were fitted by non- 
linear regression to eqn 1: 
P = Vst + (Vo - vs)(1 - e-kaPpt)/kapp + d (1) 
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Fig. 1. Slow binding inhibition of ~-thrombin by recombinant 
hirudin. Points are experimental nd lines are the best fit of the 
data to eqn 1. Inhibitor concentrations are given. 
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Fig.2. Plot of k,r,v vs r-hirudin concentrations. The apparent 
rate constant (k~pv) calculated for various inhibitor concentra- 
tions (fig. 1) were plotted vs r-hirudin concentrations. The curve 
was analyzed according to eqn 2 to obtain the kon and koff rate 
constants. Plots for all other hirudins described in this paper 
were calculated accordingly. 
The symbols v0, v, and kapv represent the initial 
velocity, steady-state velocity and an apparent 
first-order ate constant; d is a displacement term 
to account for the fact that at t = 0 the fluores- 
cence may not be accurately known. As the ob- 
served initial velocity of the reactions was 
independent of the inhibitor concentrations (cf. 
fig. 1) and the kapp values varied as a linear func- 
tion of the inhibitor concentrations (fig.2) in our 
experiments hirudin, r-hirudin and variants how- 
ed the characteristics of inhibitors obeying the 
mechanism of scheme 1 ([17,18]. 
The values of kapp were weighted according to 
the squared inverse of their standard errors and fit- 
ted to eqn 2 to obtain kon and koff: 
kapp = [kon/(1 + [S]/Km)] [I] + koff (2) 
From the relationship: Ki = kof f /kon the inhibition 
constant Ki was calculated. Table 1 summarizes the 
data as they have been obtained for hirudin, r- 
hirudin and variants. 
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Table 1 
Inhibition of thrombin by hirudin, r-hirudin and variants 
kon ](off Ki = koff/kon 
(X 10 7 M-I's -1) (x 10 -3 s -t) (X 10 -12 M) 
Natural hirudin 30.8 + 0.2 0.9 + 0.4 3 + 1 
r-Hirudin 7.8 + 0.2 1.5 + 0.2 19 + 2 
Ile27-hirudin 8.6 + 0.2 1.6 + 0.2 18 + 3 
Glu27-hirudin 10.9 + 0.02 0.4 + 0.1 4 +_ 1 
Ile36-hirudin 8.6 + 0.8 1.2 + 0.8 14 + 8 
Glu36-hirudin 10.6 + 0.6 1.7 + 0.5 16 + 4 
Ile47-hirudin 6.4 + 0.4 4.1 + 0.5 64 + 9 
Glu47-hirudin 6.9 + 1.1 13.8 + 2.4 200 + 48 
LeuS1-hirudin 8.6 + 0.5 3.2 + 0.3 34 + 4 
Asp51-hirudin 9.9 + 0.8 1.3 + 0.5 13 + 5 
The values of the kinetic parameters were determined by fitting 
primary data obtained from eqn 1 to eqn 2 and are given 
together with their standard errors 
In this way it is shown that hirudin is the most 
potent hrombin inhibitor (Ki = 2.8 pM) as is also 
indicated by its individual kon and koff rate con- 
stants. These data are changed for r-hirudin to give 
a 6-fold increased Ki value (19 pM). With respect 
to r-hirudin the variants which were modified at 
Lys 47 demonstrate a drastic effect on the inhibition 
constant. This is mainly caused by an increased kon 
(1.5 x 10 -3 s -1 for r-hirudin, 4.1 x 10 -3 s -1 for 
Ile47-hirudin and 13.8 × 10 -3 s -1 for 
Glu47-hirudin), whereas the kon rate constants are 
unaffected from the Ile 47- to Glu47-variant and are 
comparable with that for r-hirudin. Remarkable is
the low Ki value of GluZ7-hirudin which is due to 
its very low koff (0.5 x 10 -3 s - l)  and which is about 
2-fold lower than that for natural hirudin. The kon 
rate constant, however, is similar to that of all 
other r-hirudins. 
4. DISCUSSION 
Studies on the inhibition of thrombin by natural 
hirudin, r-hirudin and r-hirudin variants were per- 
formed to obtain information about the nature of 
interactions involved in thrombin-hirudin com- 
plexes. With respect o natural hirudin the struc- 
ture of  r-hirudin is missing a sulfate group on 
Tyr63: this leads to a 6-fold increase of the Ki 
value. The data for r-hirudin are in good agree- 
ment with those for desulfato-hirudin which was 
produced from the natural source by arylsulfatase 
[19] or acid treatment [4]. In this way, tyrosine 
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sulfation in hirudin seems to be involved either 
directly in the interaction with thrombin or in 
stabilizing the inhibitor structure. Therefore, r- 
hirudin and its interaction with thrombin 
represents he basis for our studies. 
As the reactive site determines the specificity of 
a proteinase inhibitor for a target proteinase [2] 
changing this special amino acid residue to an in- 
compatible one gives rise to a decrease in the/con 
rate constant by some orders of magnitude. This is 
impressively shown for the Met ~ Arg exchange in 
t~rproteinase inhibitor which decreases the/Con rate 
constant by 4 orders of magnitude for the interac- 
tion with elastase but increases this value 4 orders 
of magnitude for the interaction with thrombin 
[20]. As inhibitors react in a substrate-like manner 
with their proteinases one of the basic amino acid 
residues was thought o be the reactive site of 
hirudin. However, our results with hirudin 
variants howed only a weak influence of the basic 
amino acid residues of hirudin on the interaction 
with thrombin. It must be stressed that the/Con rate 
constant isunchanged inall cases; the koff rate con- 
stant (and therewith Ki) however is increased for 
inhibitors with mutations at position Lys 47. These 
data imply that the recognition of hirudin and 
thrombin is independent ofthe nature of a putative 
reactive site, however, the stability of the complex 
is positively influenced by Lys 47 which may 
become bound to the specificity pocket of throm- 
bin inhibiting the hydrolysis of smaller substrates. 
The rapid rate of thrombin-hirudin complex for- 
mation (cf. [4] for human and this study for bovine 
a~-thrombin) and its dependence on ionic strength 
[4] suggest that this process is a diffusion- 
controlled reaction involving mainly ionic interac- 
tions. An extended binding region may be formed 
by a contiguous surface of hydrophilic and charg- 
ed residues of the central core [21] in which the C- 
terminal part may also be involved [21]. Binding of 
a C-terminal peptide (residues 45-65) which 
recognizes thrombin but not the catalytic site [22] 
confirmed these observations. In this manner 
hirudin differs from other known proteinase in- 
hibitor proteins as its interaction with its target 
proteinase ot-thrombin does not depend strongly 
on a putative reactive site. Investigations are in 
progress to elucidate more detailed regions of 
hirudin responsible for the specific interaction with 
thrombin. 
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